umeclidinium vilanterol Anoro Ellipta
Selected indexed studies
- Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. (N Engl J Med, 2018) [PMID:29668352]
- ** (, 2017) [PMID:30212060]
- Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. (Respir Res, 2019) [PMID:31666084]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. (2019) pubmed
- PMID:30212060 (2017) pubmed
- Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. (2018) pubmed
- Drugs for COPD. (2020) pubmed
- Drugs for COPD. (2024) pubmed
- FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. (2017) pubmed
- Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. (2021) pubmed
- Anoro Ellipta: an inhaled umeclidinium/vilanterol combination for COPD. (2014) pubmed
- Umeclidinium/Vilanterol: first global approval. (2014) pubmed
- Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. (2015) pubmed